Profile
Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The Company was founded in 2007, with the corporate headquarters in Lund, Sweden. Hansa Biopharma also has operations in other European countries and in the US. The Company has been listed on the Nasdaq Stockholm since its founding. Its objective is to become a global leader in rare diseases.
Mission
Hansa Biopharma leverages its unique immunomodulating technology platform to develop innovative, lifesaving and life altering therapies, bring these to the patients with rare conditions who need them, and generate value to society at large.
Vision
A world where all patients with rare immunologic diseases can lead long and healthy lives.
Technology platform
Hansa Biopharma has developed a proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease causing antibodies. Its broad therapeutic pipeline has potential applications across transplantation enablement, autoimmune diseases, and gene therapy enablement addressing significant unmet medical needs.
Commitment to patients
At Hansa Biopharma, every employee is fully committed to developing innovative treatments to help patients with rare immunologic conditions live longer and healthier lives. With its work, the Company wants to contribute to overcome the immunological barriers that might prevent these patients from accessing treatment, therefore helping fulfil their unmet needs.
Commitment to the medical community
Hansa Biopharma’s participation in ongoing scientific exchange with the medical community is one of its highest priorities; whether through the publication of its research in peer-reviewed journals, hearing expert views through advisory meetings, the presentation of its data at scientific congresses, or the sponsorship and support given to healthcare professional organizations.
Numbers
~150 Employees
32 Different nationalities
100% Renewable electricity used
52% Women in senior position
100% Completion rate Great Place To Work Survey
